RESEARCH MONOGRAPH · KDC-MN-120

Coenzyme Q10 (Ubiquinol)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

79/100

Endogenous, well-tolerated, modest signals on specific cardiac and statin-induced endpoints

CoQ10 is endogenous, ubiquitous in mitochondrial inner membranes as the mobile electron carrier in the respiratory chain, and decreases with age plus various medications (most notably statins, which inhibit the upstream HMG-CoA reductase step in both cholesterol and CoQ10 biosynthesis). That convergence is most of why the supplement story matters at all: there are specific populations where the endogenous synthesis is plausibly inadequate.

The human trial base is unusual for a supplement-category compound. Q-SYMBIO (Mortensen 2014 in JACC-Heart Failure) showed mortality reduction in heart failure patients on 300mg/day ubiquinone over two years, which is one of the more striking positive supplement trials in cardiovascular medicine. The KISEL-10 trial (Alehagen 2015) in older adults with CoQ10 plus selenium showed cardiovascular mortality reduction over four years that was maintained on extended follow-up. These are real, properly-conducted trials with real outcomes, not just biomarker shifts.

The ubiquinol vs ubiquinone debate is partly real and partly marketing. Ubiquinol is the reduced form, presumed more bioavailable, and Kaneka's KanekaQH ubiquinol product has its own pharmacokinetic data showing better plasma elevation than equivalent ubiquinone doses. In practice the body converts back and forth at the cellular level, and most of the cardiac and mortality trial data used ubiquinone. So ubiquinol may have modestly better PK but the clinical evidence base is still mostly ubiquinone.

What we like: real human mortality endpoints in heart failure and older-adult populations, well-characterized molecule, identified populations where the deficiency makes mechanistic sense (statin users in particular, where the modest myopathy and quality-of-life signals are real). Safety profile is excellent given decades of widespread use.

What we dont like is the general-population marketing. CoQ10 in healthy young adults without statin use or heart failure shows essentially no signal on most endpoints. The disease-specific story doesn't generalize and shouldn't be sold as if it does.

Sourcing: this matters more than people think. CoQ10 is a fermentation product from various microbial sources and the trans/cis isomer ratio and the actual ubiquinone vs ubiquinol content varies significantly. Kaneka and Mitsubishi are the two major fermentation producers, most reputable supplements use one or the other. Look for documented all-trans isomer content. Stability is decent in proper storage but light-sensitive.

One of the more legitimate supplement-category compounds for specific populations, mostly a non-story for everyone else.

Evidence: 75
Mechanism: 88
Reliability: 70
Safety: 92
Sourcing: 85
Value: 75
Signal: 65
Staying power: 80

Plain-language summary Intrigue 60 / 100

Coenzyme Q10 (ubiquinol when reduced) is an essential mitochondrial cofactor that participates in the electron transport chain. Levels decline with age and with statin use. Used as a heart-failure supplement and for energy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous mitochondrial cofactor

An endogenous redox cofactor of the mitochondrial electron transport chain, declining with age and statin use, sold as a dietary supplement.

Abstract

Coenzyme Q10 (CoQ10, ubiquinone; CAS 303-98-0; molecular formula C59H90O4; molecular weight 863.34) is an endogenous redox cofactor essential for mitochondrial electron transport between Complex I/II and Complex III. The compound is synthesized from tyrosine and the mevalonate pathway; statin use reduces endogenous synthesis through HMG-CoA reductase inhibition (the same pathway used for cholesterol synthesis). Plasma and tissue CoQ10 decline with age. Supplementation has been studied for cardiovascular function (heart failure, hypertension), statin-associated muscle symptoms, and migraine prophylaxis. Bioavailability of the oxidized form (ubiquinone) is poor; the reduced form (ubiquinol) has 3- to 5-fold better bioavailability and is the preferred supplemental form for elderly subjects with reduced redox capacity. Reported research dose ranges in the literature are 100 to 400 mg of ubiquinol or higher of ubiquinone.

Mechanism of action

Endogenous electron transport chain cofactor; statin-suppressed synthesis. Antioxidant in lipid environments.

Reported research dose ranges

Reported research dose ranges in the literature are 100 to 400 mg of ubiquinol; higher of ubiquinone.

References

Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure (Q-SYMBIO). JACC Heart Fail 2014.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-120

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Coenzyme Q10 (Ubiquinol)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs